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early diagnosis and treatment, BC is nevertheless the most 
common cause of death (12.7% of total) from cancer in 
women worldwide [2]. The high mortality rate is connected to 
the high tendency of BC to spread, originating metastasis in 
different organs. Even though no evidence of tumor spread 
may be seen at the time of the primary diagnosis, a relevant 
number of axillary node-negative BC patients also develop 
local or distant metastasis [7, 8]. Bone metastases are fre-
quently diagnosed in BC patients. In 28–44% of such cases, 
they are found at the first relapse as bone-only isolated metas-
tasis [9]. In 50–70% of the cases they are found in presence of 
other relapses [10, 11], and are responsible for most of the 
morbidity and disability in metastatic BC (MBC) patients 
[12]. Over the past few years, many efforts have been made to 
improve imaging detection to discriminate better between be-
nign and malignant tissues using functional imaging taking 
into account organ metabolism and local blood flow [13]. Bio-
medical imaging is commonly involved in all the phases of 
cancer management, from screening, to prognosis up to ther-
apy, and has the advantage of being minimally invasive and 
very sensitive [14]. Although imaging has been, and still is, the 
gold standard in prognosis and metastasis monitoring, there 
are emerging alternative approaches that could be combined 
with standard methods to improve the monitoring of the dis-
ease status. For example, a growing body of evidence suggests 
that disseminated tumor cells (DTCs) in bone marrow and 
circulating tumor cells in peripheral blood (CTCs) might play 
a key role in the distant spread of the disease. CTCs detach 
from the primary tumor and, through the blood stream, reach 
secondary organs where they implant themselves giving origin 
to micrometastasis. The detection and enumeration of CTCs 
have been defined as a form of real time ‘liquid biopsy’ that 
allows the disease status and development to be monitored in 
cancer patients [15, 16]. An early detection of CTCs might 
have the potential to provide more accurate risk stratification 
for subsequent therapy decisions, or even help in tailoring ad-
ditional conventional or targeted therapies to eradicate these 
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Summary
In clinical practice imaging technologies such as com-
puted tomography (CT), positron emission tomography 
(PET)/CT and magnetic resonance imaging (MRI) are 
well-established methods for monitoring metastatic 
breast cancer (MBC) patients and for assessing thera-
peutic efficacy. However, several weeks of treatment are 
required before these technologies can offer any reliable 
information on effective disease regression, and, in the 
meanwhile, the patients are exposed to potentially un-
necessary therapy. Circulating tumor cells (CTCs) have 
been shown to be powerful prognostic and predictive 
markers and provide clinicians with valuable informa-
tion. However, in one clinical trial, an early change of 
chemotherapy based on CTC detection did not result in 
improved survival. Currently, CTC detection outside clin-
ical trials should be limited to selected clinical situations, 
i.e. increased treatment toxicity or as risk estimation.
Introduction
In women, breast cancer (BC) is the most commonly diag-
nosed type of cancer, and the risk of developing this disease 
during life is 1 in 9 [1]. According to the World Health Or-
ganization (WHO), BC is the fifth most common cause of 
death, and alone in 2008, 460,000 lethal cases were registered 
worldwide [2]. Primary BC detection and diagnosis is mainly 
based on imaging technologies such as ultrasound and digital 
mammography [3, 4]. These methods can help to distinguish 
between benign and malignant tumors [5], but cannot provide 
a definitive diagnosis [6]. Despite significant improvements in 
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than in normal tissues. On the basis of cellular avidity for 
FDG, data on the type of tumor, on its proliferation, and even 
on the presence or absence of estrogen receptors are pro-
vided. In addition, FDG-PET gives information on MBC stag-
ing, as nodal, visceral and bone metastases also usually take 
up FDG avidly [29, 30]. A comparative study between con-
ventional imaging and FDG-PET showed that the latter is 
able to predict earlier therapy response, as it can already de-
tect changes in standardized uptake values after the first 
rounds of chemotherapy [19]. FDG-PET is usually associated 
with CT, a screening technology making use of an iodinated 
contrast agent injected intravenously to improve the quality 
of the anatomical images. FDG-PET/CT scans offer very 
 accurate and precise datasets, combining anatomy inspection 
and functional analysis for a better monitoring of the tumor 
status in MBC [31]. The improved sensitivity and specificity of 
FDG-PET/CT scans makes it possible to discriminate be-
tween benign and malignant lesions in 73% of the cases, and 
to detect axillary metastasis in 100% of the cases [5]. By con-
trast, conventional imaging predicts therapy response on the 
basis of changes in tumor size, which are usually only evident 
after 2–3 months of treatment. This is a relevant point in 
 patient handling since an earlier therapy evaluation makes an 
earlier discontinuation of unnecessary, toxic or ineffective 
treatments possible.
Circulating Tumor Cells and their Prognostic Value
Metastases are probably caused by occult hematogenous 
spreading of tumor cells already during the early phases of the 
disease. Several studies support the hypothesis that dissemi-
nated tumor cells (DTCs) in bone marrow or CTCs in blood 
of cancer patients, can be regarded as precursors of clinically 
manifest distant metastases [7, 8, 32–34]. CTCs are tumor cells 
detached from primary tumors, which may reach distant or-
gans through the bloodstream, and colonize them to form 
 micrometastases [16, 35]. CTCs can even stay in this status for 
years before starting to grow further giving rise to macro-
metastasis [35, 36]. Secondary metastasis can be initiated if 
CTCs return to the blood stream and reach other organs. 
There is evidence to show that CTCs may again reach the pri-
mary tumor, starting very aggressive metastatic variants in a 
process called ‘self-seeding’ [37, 38]. DTCs can be identified 
in bone marrow, lymph nodes and blood. In particular, bone 
marrow appears to be rich in DTCs originating from different 
sites [39]. However, DTCs can only be isolated from this com-
partment by needle aspiration, which is a quite difficult and 
invasive procedure. Moreover, although DTCs have shown 
good prognostic relevance in early breast cancer, data on their 
prognostic relevance in metastatic disease are inconsistent, 
and, therefore, their clinical value unclear [40, 41]. Isolation of 
CTCs from blood samples is a more attractive option because 
of its limited invasiveness. Several methods for CTC detection 
cells before they become overt metastases. In this review, we 
discuss the different clinical approaches to monitoring tumor 
status and metastasis development with a special focus on 
MBC.
Imaging in MBC
MBC is an incurable disease and therapy is only palliative 
with the objective of reducing tumor load, slowing the meta-
static progression and increasing the quality of life [17, 18]. 
Monitoring MBC patients is particularly important during 
therapy for a prompt identification of patients who do not re-
spond to treatment, which can then be discontinued to avoid 
unnecessary side effects and to reduce treatment-associated 
complications such as neutropenia, neuropathy, and alopecia. 
Serum tumor markers such as CEA and CA 15–3 are widely 
used in breast cancer management for early and easy evalua-
tion of response or resistance to systemic therapy in patients 
with advanced disease [19]. However, due to their limited 
specificity, the use of these markers is often associated with 
additional detection methods. Biomedical imaging such as 
 ultrasound, positron emission tomography (PET), computed 
tomography (CT) and magnetic resonance imaging (MRI) are 
also commonly used in clinical practice. With these methods, 
the development of the disease can be estimated following the 
spreading of the metastasis, measuring their size and offering 
a corresponding evaluation of the response to treatment [20–
22]. Ultrasound is a ubiquitously available and simple method, 
widely used for the monitoring of liver metastases in multiple 
carcinomas. Doppler technologies can help to assess treat-
ment efficacy beyond the mere measurement of tumor size 
[23]. Several studies have shown a high sensitivity and speci-
ficity, comparable to those of CT or MRI [24, 25]. Although 
the lack of side effects and low costs facilitate repeated meas-
urements, there are limitations to the methodology such as 
unfavorable conditions, e.g. overweight, and the presence of 
metastases in locations other than the liver. MRI is used in 
different clinical contexts, such as in cancer detection, cancer 
staging and therapy-response monitoring [14]. MRI detects 
changes in tumor sizes with high sensitivity; however, to ob-
serve a significant tumor shrinkage, several cycles of therapy 
are often necessary. Therefore, MRI is not able to provide 
early information on treatment efficacy [19]. PET is com-
monly used in oncology, cardiology and neurology, with onco-
logical applications being the most common [26]. This tech-
nology makes use of positron-emitting radioisotopes, most 
often [18F]fluorodeoxyglucose (FDG), which, after intrave-
nous injection into patients, differentiate malignant from 
healthy cells [1, 27, 28]. FDG-PET produces 3-dimensional 
images based on the detection of an altered physiological sta-
tus of the tissue under examination [5]. In particular, FDG-
PET monitors the transport, the delivery and the metabolism 
of glucose – all mechanisms more pronounced in tumor cells 
18 Breast Care 2014;9:16–21 Alunni-Fabbroni/Müller/Fehm/Janni/Rack
and phenotyping, based on immunocytochemical or molecu-
lar techniques, are available. The CellSearchTM system (Veri-
dex, Raritan, NJ, USA) has been validated in the clinical mul-
ticenter setting and has proven good reproducibility. It is so 
far the only method approved by the U.S. Food and Drug 
 Administration to identify and count CTCs in breast, prostate 
and colon cancer patients. CellSearchTM is based on magnetic 
particles, coated with antibodies against the epithelial marker 
EpCAM, which isolate and enrich the EpCAM-positive CTCs 
[42]. The cells are then stained with antibodies recognizing 
CK-8, 18 and 19, and the leukocyte marker CD45, and are 
then counterstained with DAPI (4,6-diamidino-2-phenylin-
dole) to identify the nucleus. Images, corresponding to the 
stained cells, are finally displayed in a digital gallery for visual 
evaluation, with CTCs being defined as EpCAM+/CKs+/
DAPI+/CD45– cells [43, 44]. The prognostic relevance of CTC 
enumeration in MBC patients using CellSearchTM was demon-
strated for the first time by Cristofanilli et al. [45]. The detec-
tion of ≥ 5 CTC/7.5 ml peripheral blood (PB), before and 
after a new line of treatment, was associated with a shorter 
median progression-free survival (PFS) and a shorter overall 
survival (OS). Therefore, the threshold of ≥ 5 CTC/7.5 ml PB 
detected with CellSearchTM has been established for discrimi-
nating between a worse and a better prognosis, and variation 
in the number of CTCs during therapy has been found to be 
indicative of treatment response or non-response. Moreover, 
the prognostic role of CTCs associating OS to cell count has 
been shown to be dependent on the type of primary BC, and 
is more evident in estrogen receptor-positive and triple-nega-
tive MBC than in HER2-positive MBC [46, 47]. However, it 
should be mentioned that other reports have not confirmed 
these findings [48, 49]; therefore, this specific issue should be 
further investigated. The role of CTCs as prognostic markers 
has been confirmed by many other clinical studies [44, 48, 50–
54] and validated by several clinical trials [54–58], all support-
ing a strong correlation between CTC amount, PFS and OS in 
MBC. This correlation was also confirmed by a meta-analysis 
recently presented at the 2013 San Antonio Breast Cancer 
Symposium [59]. In that investigation, Bidard and coworkers 
analyzed individual data of 1,944 MBC patients and found 
that CTC count and changes in their number during therapy 
were significantly associated with PFS and OS. They con-
cluded that CTC count significantly improves the prognostica-
tion of MBC outcome and demonstrated the superiority of 
CTCs over serum tumor markers.
Although involving early BC patients and not MBC, it is 
also worth mentioning the German multicenter SUCCESS 
trial, which was the largest study so far run to verify the asso-
ciation between CTC enumeration and survival rate [60]. So 
far, approximately 2,000 early BC patients treated with adju-
vant chemotherapy have been monitored with respect to their 
CTC count by CellSearchTM. In 21.5% of patients at least 
1 CTC was detected before the start of systemic treatment, 
whereas after completion of chemotherapy, 22% of patients 
presented with persisting CTCs. After a median follow-up 
of 35 months (range 0–54), the presence of CTCs before and 
after systemic treatment predicted poor disease-free survival 
(DFS) (p = 0.0001 and p = 0.04) and OS (p = 0.0002 and 
p = 0.03). The prognostic relevance of CTCs in early BC was 
also confirmed by a recent pooled analysis on 3,172 patients, 
in which the presence of CTCs was significantly related to 
shorter PFS (p < 0.001, hazard ratio (HR) 2.02, 95% confi-
dence interval (CI) 1.63–2.50) and OS (p < 0.001, HR 2.57, 
95% CI 1.96–3.37).
Comparison between Imaging and CTCs  
as Predicting Factors in MBC
The clinical findings correlating the CellSearchTM-based 
 detection of ≥ 5 CTCs/7.5 ml PB to PFS and OS both before 
and 4 weeks after the start of a new line of chemotherapy in 
MBC opened to the possibility to use CTCs as new prognostic 
and predictive markers. However, to verify if the number of 
CTCs correlates with standard imaging determination of dis-
ease progression, several validation studies have been con-
ducted. In 2006, the first direct comparison between CTC 
count and radiological imaging in MBC patients (n = 138) was 
published [61]. Before starting the therapy, all patients had 
CT and/or MRI of chest and abdomen, a whole body scan and 
CTC count by CellSearchTM. Disease status was then moni-
tored every 9 and 12 weeks depending of treatment, using the 
same clinical and imaging modalities. While both methods 
could equally predict PFS and OS for patients receiving the 
first-line treatment, CTCs allowed an earlier and more accu-
rate OS assessment in higher lines of treatment (p = 0.0009 
for CTCs, p = 0.2209 for radiological response). Furthermore, 
the reproducibility of CTC counts was increased compared to 
radiological assessment with an inter-reader variability of 0.7 
and 15.2%, respectively. This study showed for the first time 
that CTC enumeration is a reliable and accurate way to moni-
tor disease progression, offering an earlier and more repro-
ducible MBC monitoring than standard anatomic imaging 
methods.
The prognostic significance of CTC enumeration by Cell-
SearchTM and FDG-PET/CT metabolic imaging was further 
evaluated in a retrospective analysis of MBC patients (n = 
115) during systemic treatment with standard therapies [62]. 
CTC counting and PET/CT imaging were performed before 
starting therapy and monitoring was repeated at the midpoint 
of therapy (9–12 weeks). The authors found a concordant 
number of CTCs to FDG-PET/CT response/non-response in 
68 (67%) patients and a concordant number of CTCs to FDG-
PET/CT progression/non-progression in 76 (75%) patients. In 
the 34 response/non-response discordant cases (33%), 31 pa-
tients had ≤ 5 CTCs/7.5 ml (91%) and only 3 (9%) showed 
≥ 5 CTCs/7.5 ml PB at therapy midpoint. In the 26 progres-
sion/non-progression discordant cases (25%), 22 (85%) 
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bers were detected in case of lymph node and/or chest wall 
metastasis (n = 23; mean 1.4 ± 2.0 CTCs), compared to lung 
and /or pleural metastases (n = 25; mean 2.9 ± 8.1 CTCs) and 
liver metastasis (n = 9; mean 8.9 ± 16.4 CTCs). CTCs enumer-
ation did not predict OS in patients without metastasis (p = 
0.4111) and in those with only bone metastasis (p = 0.3552), 
while CTCs predicted OS in patients who presented bone 
 metastasis associated with metastasis also in other sites (p = 
0.0008). In summary, the study correlated the number of 
CTCs detected in MBC patients and the site of metastasis, 
with significantly higher CTC numbers if bone metastasis 
were present. Among patients with bone metastasis, a clear 
difference in CTC count was observed between patients with 
diffuse skeletal metastasis and those with few bone lesions. 
Among patients with metastasis in other tissues, CTC num-
bers were higher in case of liver metastasis with respect to soft 
tissues, lung and/or pleural metastasis. These observations 
suggest that the entity of the tumor shedding, and therefore 
the number of detected CTCs, might be connected to the site 
of metastasis, and that a higher number of CTCs might indi-
cate bone involvement. The same authors expanded the study 
evaluating the predictive significance of CTC enumeration 
and FDG-PET/CT in patients with only bone metastasis de-
rived from BC and without any visceral metastasis (n = 55) 
[65]. All patients underwent FDG-PET/CT and CTC counting 
by CellSearchTM before starting a new line of standard treat-
ment. Disease status was further evaluated after 2 and 
4 months from the beginning of the study. 43 (78%) patients 
showed concordant FDG-PET/CT and CTC results. Among 
the 12 patients with discordant results, 8 (66%) were found 
with ≥ 5 CTCs/7.5 ml PB with no evidence of progressive dis-
ease identified by FDG-PET/CT, while 4 (33%) were found 
with ≤ 5 CTCs/7.5 ml PB and evidence of progressive disease. 
At follow-up, CTC counts and FDG-PET/CT monitoring 
were significantly associated with PFS (p = 0.02 and 
p < 0.0001, respectively) and to OS (p = 0.02 and p = 0.01 re-
spectively). However, in multivariate analysis, FDG-PET/CT 
was the only predictive factor for PFS (p < 0.0001), while 
 estrogen receptor status was the only predictive factor for OS 
(p = 0.01).
To our knowledge, it has not been shown so far that an 
early change of chemotherapy can improve OS. In particular, 
using imaging techniques to assess tumor response, it has not 
been proven that a second line of treatment can improve OS 
in patients not responding to the first line of chemotherapy. In 
this respect, Smerage et al. [66] recently presented the results 
of the SWOG S0500 trial, evaluating a CTC-guided change of 
chemotherapy regimen in MBC. Patients with elevated CTCs 
at baseline and also elevated CTCs after 21 days of therapy 
were randomly assigned to either continue initial therapy 
until clinical progression or to change to a second-line chemo-
therapy of the physician’s choice immediately at cycle 2. 123 
patients were randomly assigned to either maintain original 
chemotherapy (n = 64) or switched to new chemotherapy 
 patients had ≤ 5 CTCs/7.5 ml PB, while 4 (15%) showed 
≥ 5 CTCs/7.5 ml PB at therapy midpoint. The authors sug-
gested a relationship between CTC counts and tumor meta-
bolic activity. Moreover, they found that both FDG-PET/CT 
response/non-response and FDG-PET/CT progression/non-
progression can reliably predict prognosis in those patients for 
whom the CTC number is ≤ 5 CTCs/7.5 ml PB at mid-therapy 
(p = 0.0086 and p = 0.0018, respectively), while detection of 
≥ 5 CTCs/7.5 ml PB during therapy can reliably monitor dis-
ease progression in MBC patients.
In the same year, a prospective longitudinal clinical study 
was conducted to validate the hypothesis that the number of 
CTCs, detected with CellSearchTM, and the fixed threshold of 
5 CTCs/7.5 ml PB correlates with the imaging determination 
of disease progression in MBC patients (n = 81) [63]. Before 
starting a new line of therapy, PB samples were collected and 
analyzed, and a complete imaging evaluation was performed. 
PB samples collection and imaging monitoring were repeated 
in intervals of 9 and 12 weeks, corresponding to new treat-
ment cycles. This study showed that CTC enumeration was 
strongly correlated to radiographic determination of disease 
progression in patients receiving treatment for MBC. Impor-
tantly, correlation was applicable not only to the time of imag-
ing, but also to CTC results obtained up to 9 weeks in advance 
with respect to imaging. Moreover, the number of CTCs with 
respect to the threshold of 5 CTCs/7.5 ml PB was a reliable 
marker of PFS in the patient cohort. In conclusion, the results 
of this study supported the importance of CTC quantification 
and its role in monitoring the disease status of MBC in combi-
nation to the standard imaging methods. FDG-PET/CT has 
been shown to be a very sensitive method with respect to con-
ventional imaging approaches for detecting MBC metastasis, 
because of the combination of anatomic and metabolic data-
sets. To understand if there is a correlation between the num-
ber of CTCs and the metabolic activity of metastasis in MBC 
patients, a new study was conducted by De Giorgi et al. [64] 
to correlate CTCs and bone metastasis detected by FDG-
PET/CT in patients (n = 195) diagnosed with relapsed/pro-
gressive MBC. Before being enrolled in the study, all patients 
were diagnosed with relapsed/progressive MBC according to 
standard clinical and imaging procedures. At the beginning of 
the study, patients underwent FDG-PET/CT and provided PB 
samples for CTC enumeration by CellSearchTM. In the patient 
cohort, 103 (53%) showed ≤ 5 CTCs/7.5 ml PB at relapse/pro-
gression and 92 (47%) ≥ 5 CTCs/7.5 ml PB. In the group with 
≥ 5 CTCs/7.5 ml PB, 83 patients (90%) showed bone metasta-
sis; in the group of 137 patients with bone metastasis at re-
lapse/progression, 83 (61%) had ≥ 5 CTCs/7.5 ml PB and 54 
(39%) had ≤ 5 CTCs/7.5 ml PB. The authors described a good 
correlation between the number of CTCs found in patients 
and the presence of bone metastasis detected by FDG-PET/
CT, with higher numbers of CTCs detected in patients with 
more extensive bone metastasis. Among patients with no 
bone metastasis detected by FDG-PET/CT, lower CTC num-
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prognostic relevance of CTCs. Since chemotherapy treatment 
is usually associated with a number of serious side effects, 
CTCs could help to avoid unnecessary toxicity when the ex-
pected treatment efficacy is low. Additionally, CTC pheno-
typing could contribute to a better individualized systemic 
treatment. Changes in the tumor phenotype are a known 
 phenomenon and may lead to treatment changes in up to 20% 
of patients. Consequently, CTC phenotyping could be used as 
an easily accessible, real-time, liquid biopsy of tumor cells that 
disseminate from the tumor into the blood stream. Clinical 
 intervention trials such as DETECT III are currently being 
performed to evaluate the predictive role of CTCs to tailor 
targeted treatment approaches in metastatic diseases. In con-
clusion, CTC detection and phenotyping offers valuable infor-
mation on tumor load and tumor biology, and has been shown 
to be a valid complementary prognostic method to standard 
imaging. Nevertheless, additional studies and clinical trials 
will be necessary to establish further applications of CTCs in 
everyday clinical care.
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(n = 59). Changing to an alternative chemotherapy did not im-
prove OS for patients whose CTCs did not decrease after the 
first cycle of chemotherapy (p = 0.83). Furthermore, this 
group of patients with persistently high CTC counts had a rel-
atively short median OS (13 months) compared to patients 
with initially ≤ 5 CTCs/7.5 ml PB (35 months) or CTCs that 
dropped ≤ 5 CTCs/7.5 ml PB after the first cycle of chemo-
therapy (23 months). CTCs might therefore detect a subgroup 
of patients with resistance to chemotherapy and the need for 
other treatment approaches.
Conclusions
The vast literature published during the last few years 
strongly supports the important role of CTCs in metastasis 
formation. While the prognostic role of CTCs has been clearly 
shown for early BC and MBC, the optimal role of CTCs in 
everyday clinical care is still unclear. In advanced disease, 
CTCs could predict response to chemotherapy and endocrine 
treatment effectively, and earlier than imaging tools, and can 
provide information going beyond mere tumor load. The 
prognostic information is of potential value, e.g. for the iden-
tification of patients with a high risk of rapid tumor progres-
sion and the need for chemotherapy. However, a recent trial 
has shown that early change to an alternative chemotherapy 
could not improve the prognosis of these patients despite the 
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